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Abstract
As lymphatic filariasis (LF) programs move closer to established targets for validation elimi-
nation of LF as a public health problem, diagnostic tools capable of supporting the needs of
the programs are critical for success. Known limitations of existing diagnostic tools make it
challenging to have confidence that program endpoints have been achieved. In 2019, the
World Health Organization (WHO) established a Diagnostic Technical Advisory Group
(DTAG) for Neglected Tropical Diseases tasked with prioritizing diagnostic needs including
defining use-cases and target product profiles (TPPs) for needed tools. Subsequently, dis-
ease-specific DTAG subgroups, including one focused on LF, were established to develop
TPPs and use-case analyses to be used by product developers. Here, we describe the
development of two priority TPPs for LF diagnostics needed for making decisions for stop-
ping mass drug administration (MDA) of a triple drug regimen and surveillance. Utilizing the
WHO core TPP development process as the framework, the LF subgroup convened to dis-
cuss and determine attributes required for each use case. TPPs considered the following
parameters: product use, design, performance, product configuration and cost, and access
and equity. Version 1.0 TPPs for two use cases were published by WHO on 12 March 2021
within the WHO Global Observatory on Health Research and Development. A common TPP
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characteristic that emerged in both use cases was the need to identify new biomarkers that
would allow for greater precision in program delivery. As LF diagnostic tests are rarely used
for individual clinical diagnosis, it became apparent that reliance on population-based sur-
veys for decision making requires consideration of test performance in the context of such
surveys. In low prevalence settings, the number of false positive test results may lead to
unnecessary continuation or resumption of MDA, thus wasting valuable resources and time.
Therefore, highly specific diagnostic tools are paramount when used to measure low thresh-
olds. The TPP process brought to the forefront the importance of linking use case, program
platform and diagnostic performance characteristics when defining required criteria for diag-
nostic tools.
Author summary
High quality diagnostic tools are an essential component of lymphatic filariasis (LF) pro-
grams. Currently, diagnostic tools are used by national programs to establish baseline
endemicity, monitor progress of program interventions, determine when interventions
can be stopped, and surveillance. For years, LF programs have relied on diagnostic tools
that have been central to informing key program decisions but were not necessarily
designed to undertake the roles for which they are used. Known limitations of existing
diagnostic tools make it challenging to have confidence that program endpoints have
been achieved. Target product profiles (TPP) provide product requirements to guide
developers and manufacturers in their efforts to design tools fit for purpose. However,
development of diagnostic tools used in public health programs requires consideration of
aspects beyond those considered when developing diagnostic tools used for clinical diag-
nosis. The TPP process for two LF use cases brought to the forefront the importance of
linking use case, program platform and diagnostic performance characteristics when
defining required criteria for diagnostic tools.
Introduction
Lymphatic filariasis (LF) is a mosquito-transmitted neglected tropical disease (NTD) caused
by infection with filarial parasites (Wuchereria bancrofti, Brugia malayi, or Brugia timori) [1].
Over time, infection can lead to damage of the lymphatic vessels, leading to hydrocele, lymph-
edema, and elephantiasis. People who live with chronic and disabling manifestations of LF
may experience reduced economic productivity and social stigma [2]. The Global Programme
to Eliminate Lymphatic Filariasis (GPELF) aims to eliminate LF as a public health problem
with a two-armed approach: stopping the spread of infection through mass drug administra-
tion (MDA) of antifilarial medicines and alleviating suffering among patients through morbid-
ity management and disability prevention. There is little debate on the considerable progress
toward LF elimination. As of 2019, 22 of 72 endemic countries had reduced infection levels
below target thresholds and no longer required MDA nationally. The World Health Organiza-
tion (WHO) has acknowledged 17 of these countries as having met criteria for eliminating LF
as a public health problem [3]. It is estimated approximately 97 million cases have been pre-
vented or cured through the strategies recommended by WHO, due in part to delivery of more
than 8.2 billion treatments to more than 923 million people [3,4]. In addition, more than USD
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$100 billion in economic losses have been averted [5]. Despite this progress, critical limitations
such as diagnostic tool deficiencies, inability to scale up interventions in some areas and pau-
city of surveillance guidance need to be addressed to reach established program goals [6].
In 2017, WHO recommended the combination of ivermectin, diethylcarbamazine and
albendazole (IDA), for MDA in countries and territories not co-endemic for onchocerciasis or
loiasis [7]. A single dose of this triple drug combination is more effective at clearing and sus-
taining microfilariae (Mf) clearance than the standard two-drug combinations used since the
start of GPELF [8,9]. Sustained clearance of Mf indicates a potential sterilizing effect on adult
worms, an outcome not observed when using combinations of albendazole with either diethyl-
carbamazine or ivermectin. As such, it is possible fewer rounds of MDA using IDA will be
needed to interrupt transmission compared to two-drug combinations which are typically pro-
vided annually for five years or longer.
Currently, program progress is monitored by testing residents of communities at an admin-
istrative level, often a district, under treatment for the presence of circulating filarial antigen
(CFA) for W. bancrofti and antifilarial antibodies (BmR1) for Brugia spp. The Alere Filariasis
Test Strip (FTS; Abbott, United States), which measures CFA, and the Brugia Rapid Test
(BRT; Reszon Diagnostics, Malaysia), which measures antifilarial antibodies, are used in areas
endemic for W. bancrofti and Brugia spp., respectively. Demonstration that the population
prevalence of positive tests for these analytes is below a defined threshold in a transmission
assessment survey (TAS) is an indication that LF is no longer a public health problem in the
area assessed [10]. While this monitoring approach was effective for the two-drug strategy,
which is typically conducted at least five years after initiating MDA, follow-up evidence from
initial IDA safety and efficacy studies showed persistence of CFA for five years after a single
round of IDA-MDA even with sustained clearance of Mf [9,11]. Thus, measuring CFA alone
may not be an adequate way to monitor LF elimination programs using IDA. While testing for
Mf is possible, it is not ideal in program settings because of limitations in technical capacity,
low sensitivity after MDA and the nocturnal periodicity of the parasite in many endemic set-
tings, making blood collection inconvenient. To continue using the existing monitoring and
evaluation (M&E) framework without modification, new diagnostic tools are urgently needed
to detect the presence of viable worms following introduction of IDA.
Along with better tools to conduct M&E, and as more national programs reach established
benchmarks and stop MDA, the importance of monitoring for resurgence through surveil-
lance activities also increases. WHO recommends repeating the TAS twice at 2- to 3-year
intervals after MDA has stopped. Demonstration that the number of antigen-positive children
in each survey remains below the target threshold provides evidence that transmission is not
sustainable. While the TAS is useful for stop-MDA decisions, it is not statistically powered to
measure reductions in prevalence or incidence over time or to be a sensitive measure of recru-
descence in transmission potential. Limitations of available diagnostic tests compound the sur-
vey design limitation. CFA can take 12 months or more to appear after incident infection and
may persist several months to years after adult worms can no longer reproduce or have died
[9,12,13]. Similarly, the presence of antifilarial antibodies may be indicative of prior exposure
to Brugia spp. and may not represent an active infection or viable parasites [14–16]. Existing
diagnostic tools have been adequate for mapping disease distribution and monitoring progress
of interventions, but new diagnostics targeting analytes that represent recent exposure or pre-
patent infection are needed to inform LF post-MDA and post-elimination surveillance.
As LF programs move closer to elimination targets, diagnostic tools capable of supporting
the needs of the program are critical for success. For both stopping IDA and surveillance,
known limitations of existing diagnostic tools make it challenging to have confidence that pro-
gram endpoints have been achieved. The need for high quality diagnostics is not unique to LF,
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and critical gaps exist for many NTDs. As suggested in a recent publication, four important
considerations are necessary when developing new diagnostic tools for NTD programs–(i) rec-
ognition that specificity determines the utility of diagnostic tools in low prevalence settings;
(ii) consideration of the M&E framework in which the diagnostic tools will be used; (iii) will-
ingness to move away from a single-test paradigm; and (iv) adaptation of M&E decision rules
to reflect test performance [17]. As control and elimination targets were considered in devel-
opment of a new NTD road map for 2021–2030, common gaps across the diverse NTD portfo-
lio were highlighted [6]. There was recognition that a concerted effort was needed to address
diagnostic deficiencies, or the NTD community would risk falling short of the new targets. In
2019, in acknowledgment of the identified priority, WHO established a Diagnostic Technical
Advisory Group (DTAG) tasked with reviewing and prioritizing diagnostic needs for NTD
programs, defining use-cases and target product profiles (TPPs) for needed tools, working
with national NTD programs and implementing partners to support test development and val-
idation, and providing WHO with guidance and recommendation on adoption of new diag-
nostics [18]. Subsequently, disease-specific DTAG subgroups, including one focused on LF,
were established to follow a standardized process to develop TPPs and use-case analyses to be
used by product developers. Here, we describe the development of two priority diagnostic
TPPs for LF.
Methods
Upon recommendation of the DTAG, WHO formed a group (known as the LF subgroup) of
LF technical experts, end users and other stakeholders which met virtually in April 2020 to exe-
cute the process of developing TPPs for two priority use cases, stopping IDA and surveillance.
TPPs were intended to facilitate expeditious development of new diagnostic assays addressing
prioritized public health needs. Utilizing the WHO core TPP development process as the
framework [18], and following well-established quality planning methodologies [19,20], the LF
subgroup convened online a total of four times to discuss and determine attributes required
for each use case (Fig 1).
TPPs for each use case considered the following parameters: product use, design, perfor-
mance, product configuration and cost, and access and equity. Initial Draft 0 requirements in
each TPP were selected based on landscape analyses, use case needs analysis and diagnostics
performance modeling developed in late 2019 through a consultative process coordinated by
WHO Department of the Control of Neglected Tropical Diseases and facilitated by a certified
quality management expert. The LF subgroup critically reviewed and modified the zero draft
Fig 1. WHO Core TPP process.
https://doi.org/10.1371/journal.pntd.0009968.g001
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where warranted. For certain elements in each use case, parameters were defined at the outset,
and assumptions were made to move forward with sensitivity and specificity calculations
(Tables 1 and 2). While there is no WHO target threshold for surveillance, researchers have
proposed a provisional threshold of 5% antibody prevalence in children [21]. This provisional
threshold was used for calculations in the surveillance TPP. The LF subgroup finalized the
TPP details, and draft 0.1 TPPs were posted for 30 days on the WHO website for public com-
ment in September 2020. A link to the public comment site was sent out to stakeholders
including researchers, non-governmental organizations, ministries of health and other NTD
program partners. Comments received were discussed at the final meeting of the LF subgroup
in November 2020, and TPPs were revised accordingly to generate version 1.0 TPPs.
Results
Version 1.0 TPPs for two use cases, stopping IDA and surveillance, were published by WHO
on 12 March 2021 within the WHO Global Observatory on Health Research and Development
[22,23]. Select TPP features and their associated requirements are presented in Tables 3 and 4.
Discussion
The GPELF strategy is predicated on the assumption that if antifilarial medicines are delivered
consistently over a defined period, transmission will be reduced to a level at which it is no lon-
ger sustainable even in the absence of MDA. A clear threat to LF elimination is the inability to
assess accurately if continued intervention is warranted. Prior to the launch and in the early
years of GPELF, detection of Mf in peripheral blood was used routinely to identify individuals
for treatment [24]. Detection of Mf in thick blood films served as an indication of viable adult
Table 1. Parameters and assumptions for use case 1: stopping IDA.
Calculations were based on testing a 1% infection prevalence threshold and considered two potential scenarios:
• "Single test" approach in which a new assay would replace the current tools (i.e., FTS/BRT) in the TAS; and
• "Decision confirmatory test" approach in which the new diagnostic test would be used as a decision
confirmatory assay on individuals testing positive by FTS/BRT. Results of the confirmatory test would be used to
make a program decision at a population level as opposed to an individual clinical treatment decision or
confirmation of the first test result.
Assumptions made for sensitivity and specificity calculations:
• FTS/BRT is 90% sensitive for detecting Mf-positive individuals; FTS specificity 100% outside of Loa loa co-
endemic areas
• Survey design: 30-cluster; equal probability of selection
• “Single test” approach: 80% power to correctly conclude that a defined population with a true prevalence�0.2%
(ideal) or = 0% (minimum) is below the 1% threshold
• “Decision confirmatory test” approach: 80% power to correctly conclude that a defined population with a true
prevalence�0.5% (ideal) or� 0.2% (minimum) is below the 1% threshold
• α�5% (i.e., Type 1 error rate); meaning that using this diagnostic test, the survey would incorrectly conclude
that prevalence in a defined population is below the 1% threshold<5% of the time
https://doi.org/10.1371/journal.pntd.0009968.t001
Table 2. Parameters and assumptions for use case 2: Surveillance.
Assumptions made in sensitivity and specificity calculations:
• The diagnostic test would be used to identify evidence of transmission hotspots; calculations assume a lot quality
assurance sampling approach where the goal is the upper 1-sided confidence interval of the prevalence is <5%
• The calculations account for a finite population correction for village level prevalence; villages population sizes
300 to 5,000 people were considered
• α�5% (i.e., Type 1 error rate); this means that using this diagnostic test, the survey would incorrectly conclude
prevalence in a defined population is below the 5% threshold<5% of the time
• 80% power to correctly conclude prevalence is below the 5% threshold in a defined population with a true
prevalence�2% (ideal); and�1% (minimum)
https://doi.org/10.1371/journal.pntd.0009968.t002
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worm infections and provided evidence needed to make treatment and programmatic deci-
sions. However, logistical challenges were encountered because of the requirement for night
blood collections. Furthermore, it was increasingly difficult to detect Mf in populations after
multiple rounds of MDA [25]. Many of the limitations experienced with Mf detection were
addressed with the introduction of tests to detect CFA. The detection of CFA served as a rea-
sonable proxy for infection, and importantly, could be conducted with blood collected any
time of the day, thus eliminating the need for night blood collections. The development of a
rapid test to detect CFA in the 1990s was considered a turning point for LF elimination
[26,27]. Logistical barriers of night blood collection for Mf detection were largely overcome,
and the wide availability of a highly sensitive and specific CFA test gave confidence that pro-
gram targets had been achieved. However, like the observed decline in Mf prevalence after
treatment, antigenemia also declined in populations after multiple rounds of treatment [25].
Recently, the apparent lack of specificity of CFA tests in areas co-endemic for Loa loa and per-
sistence of CFA in areas treated with IDA have posed problems for accuracy in decision mak-
ing for surveillance and stopping MDA [9,13,28,29]. Despite known limitations, GPELF has
relied on diagnostic tools that have been central to informing key program decisions but were
not necessarily designed to undertake the roles for which they are used. However, limitations
of the tools for use as multi-purpose diagnostics have largely been outweighed by their ability
to drive program advances. Although the CFA test continues to be suitable in some settings
such as areas that use one of the standard two-drug combinations, its use is inadequate in
other settings. Hence, it is imperative to strive for efficient ways to strengthen programs,
improve upon programmatic feasibility and develop tools fit for purpose. The need for high
quality diagnostic tools to accurately assess the status of programs was recognized by the
DTAG in 2019, highlighting the urgency to identify rapid solutions. The TPP development
Table 3. Select characteristics of needed test to support stopping IDA decisions.
Feature Ideal requirement Minimum requirement
Target analyte Antigen(s) or other biomarker(s) specific for Wuchereria
bancrofti, Brugia malayi or Brugia timori and indicative of the
capability to reproduce at the time of testing or thereafter. The
absence of biomarker must indicate the worms are either not




"Single test" approach: > 60%
"Decision confirmatory test" approach: > 85%






"Single test" approach: > 99.7%
"Decision confirmatory test" approach: > 96%





Table 4. Select characteristics of needed test for surveillance of lymphatic filariasis.
Feature Ideal requirement Minimum
requirement
Target analyte Antibody(s) or other biomarker(s) specific for early exposure or pre-





>99% sensitivity >85% sensitivity
Diagnostic/clinical
specificity
>99.8% specificity >98.8% specificity
https://doi.org/10.1371/journal.pntd.0009968.t004
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process allowed for careful consideration and a systematic approach to outline characteristics
of diagnostic tools needed to overcome current barriers.
A common TPP characteristic that emerged in both use cases was the need to identify new
biomarkers that would allow for greater precision in program delivery. While introduction of
IDA represents potential to accelerate LF elimination, the full potential of the new drug regi-
men may not be reached if it is not coupled with improved ways to effectively determine when
it is safe to stop MDA. In areas where multiple rounds of MDA have been conducted, antigen
or antibody positive children identified in TAS likely represent recent exposure or infection.
However, in areas where IDA is used, positive signals in TAS are challenging to interpret. The
IDA TPP underscores the urgent need to identify alternative indicators to CFA and antifilarial
antibodies to BmR1. Given the current M&E framework in which the diagnostic tools are
used, accuracy and efficiency in decision making will be strengthened if infection with worms
capable of reproduction can be differentiated from infection with sterile or dead worms that
do not pose a threat to sustained transmission. Similarly, the surveillance TPP reflects a need
to identify markers capable of accurately distinguishing signals that denote immediate threats
from those representing historic or waning signals in the population. In the surveillance con-
text, it is assumed that detecting the earliest opportunity to address recrudescence or ongoing
transmission will be critical. Current evidence suggests antibody responses often appear
months to years before CFA or Mf and could be an early warning signal during surveillance
[12]. Importantly, antibody responses decline over time, and the absence of antibody
responses provides evidence of the absence of transmission [30]. However, in the context of
more recent transmission, it has been challenging to distinguish recent exposures from persis-
tent responses to past exposures or infections. Additionally, existing antibody tests often lack
the level of specificity needed [14,31,32], and some degree of non-specific reactivity is expected
with most tests. This issue complicates the ability to determine an antibody threshold indica-
tive of recent or ongoing transmission making interpretation of antibody results complex. For
example, apparent antibody signals in LF non-endemic areas of Togo were higher than in LF
endemic areas, making it difficult to determine if program action was required [33]. The LF
DTAG subgroup recognized that discovery and validation of alternative markers may require
significant time and effort. However, the high-risk nature of the research effort was viewed as
essential to make necessary advances.
The utility of a diagnostic tool is often defined by its performance characteristics (e.g. sensi-
tivity and specificity). While some of these parameters are mutable, high sensitivity and speci-
ficity are often considered optimal benchmarks to achieve. Defining the parameters of the IDA
and surveillance TPPs required a shift from traditional considerations of ideal performance.
Unlike some disease control and elimination programs (e.g. HIV), LF diagnostic tests are
rarely used to make individual clinical diagnoses. Instead, tests used to make program deci-
sions at a population level are applied according to a defined M&E framework. A typical TAS
is conducted via cluster-based sampling of approximately 1,700 young children in a defined
evaluation unit (EU) (e.g. district) [10]. Program decisions are made by comparing the
observed number of positive test results in a survey against a target threshold. The observed
number of positive results is dependent on the prevalence of positive tests, which includes true
positives and those testing positive falsely. As such, additional considerations are necessary
when interpreting test results since imperfections in performance of diagnostic tools can be
compounded when applied across a surveyed population. When comparing survey results to a
low threshold and using a diagnostic tool with<100% specificity, false positive results may
drive an incorrect program decision, particularly in low prevalence settings, even if program
interventions have been successful. In TAS, the number of false positives may lead to unneces-
sary continuation or resumption of MDA, thus wasting valuable resources and time.
PLOS NEGLECTED TROPICAL DISEASES Development of two LF TPPs
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0009968 November 15, 2021 7 / 11
Therefore, highly specific diagnostic tools are paramount when used to measure low thresh-
olds [17]. The sensitivity requirements defined in the IDA TPP appear low by conventional
standards, but as LF infections become increasingly rare the sensitivity of a diagnostic test has
very minimal impact on positive predictive value [17]. Allowing lower sensitivity does not
automatically imply that the ability to make correct decisions based on survey outcomes will
be poor. However, it is possible that survey designs may need to be adjusted either by increas-
ing the sample size or by decreasing the critical cut off to ensure that the statistical parameters
are within the desired range (e.g. 5% alpha error and 75% power in the TAS).
As performance requirements were determined for each use case, it became apparent that
reliance on population-based surveys for decision making requires consideration of test per-
formance in the context of such surveys. The TPP process brought to the forefront the impor-
tance of linking use case, program platform and diagnostic performance characteristics when
defining required criteria for diagnostic tools. For the surveillance TPP, the absence of well-
defined M&E guidelines led to the need to make several assumptions that may change as sur-
veillance guidance is updated. For the surveillance TPP, an assumption was made that a stand-
alone population-based survey will be conducted, and concurrently, a critical assumption was
made that the EU definition is likely to change. With a shifting trend toward identification and
response to hotspots to verify elimination of transmission, the geographic area to consider will
shrink, resulting in assessment of relatively small communities as the unit of programmatic
action (e.g. village). With this shift, survey sample sizes will be constrained, and performance
requirements of diagnostic tools will be affected. Although the threshold assumed for the sur-
veillance TPP (5%) was higher than the IDA TPP (1%), the defined sensitivity and specificity
requirements were more stringent. The requirement to distinguish a signal that triggers a pub-
lic health response from background reactivity (1–2%) led to the need for a diagnostic tool sen-
sitive enough to detect true infections but also specific enough to exclude false positive test
results. The parameters outlined in the surveillance TPP illustrate the need for test developers
to understand test performance constraints that are critical to making effective decisions at the
community level.
The need for highly specific diagnostic tools extends beyond LF and is applicable to other
NTDs with low target thresholds, especially for disease programs that rely on population-
based surveys when making decisions. Following the same standardized WHO process for
developing TPPs, similar requirements for high specificity are reflected in recently published
TPPs for onchocerciasis, schistosomiasis, and soil-transmitted helminths [34–36]. While there
is inherent risk in setting high specificity standards, it is an opportunity to identify innovative
and flexible solutions to meet criteria. It will be difficult to achieve such extreme standards in a
single test, and the NTD community will have to evaluate alternative strategies such as testing
approaches based on two tests. For the IDA TPP, a confirmatory test approach was considered.
While a confirmatory test in this case was to confirm a programmatic decision and not an
individual-level diagnosis, it still represents a multiple test strategy that will allow for specificity
requirements of any single test to be relaxed. As new tools are developed, it is critical to stan-
dardize a framework in which new tools are validated. To ensure timeliness of results and
comparability across settings, WHO can play an important role in guiding the standards by
which tools are evaluated. The TPP development framework, guided by the DTAG and
anchored by WHO, helps to assure a unified approach to identify and prioritize diagnostic
needs according to program needs. Additionally, regular review of established TPPs will
ensure that alignment with program needs is maintained.
The LF TPP development process confirmed the importance of prioritizing specificity
requirements and the need to consider survey designs. While it was beyond the scope and
mandate of the LF DTAG subgroup to consider changes to M&E frameworks, it emphasized
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the importance of maintaining close linkages between the DTAG and WHO M&E working
group to ensure efforts are aligned for the benefit of NTD control and elimination programs.
With clear M&E guidelines and appropriate diagnostic tools, national programs will be better
able to plan activities to measure progress toward the 2030 goals.
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